Ferrarotto Hospital, University of Catania, Catania, Italy.
J Thromb Haemost. 2013 Jun;11 Suppl 1:316-29. doi: 10.1111/jth.12219.
Recurrent atherothrombotic events in patients with acute coronary syndromes (ACS) and/or those undergoing percutaneous coronary intervention (PCI) are essentially platelet-driven processes, underscoring the need for effective pharmacological platelet inhibition. Dual antiplatelet therapy with aspirin and clopidogrel has been, for over a decade, the mainstay of antiplatelet management in ACS/PCI. However, atherothrombotic events continue to occur in a relevant proportion of subjects despite the benefit of this combination, which has led to the clinical development of newer and more potent antiplatelet drugs. Two of these, prasugrel and ticagrelor, have been recently approved for clinical use. The scope of this manuscript is to provide an up-to-date overview on new antiplatelet drugs in the setting of ACS and PCI, including the most recent advances on newly approved agents as well as on emerging compounds in clinical development.
急性冠状动脉综合征（ACS）和/或经皮冠状动脉介入治疗（PCI）患者的复发性动脉粥样血栓事件本质上是血小板驱动的过程，这凸显了有效抑制血小板药物治疗的必要性。阿司匹林和氯吡格雷双联抗血小板治疗在过去十年中一直是 ACS/PCI 中抗血小板管理的主要方法。然而，尽管这种联合治疗有一定的益处，仍有相当一部分患者发生动脉粥样血栓事件，这导致了新型、更有效的抗血小板药物的临床开发。其中两种药物，普拉格雷和替格瑞洛，最近已被批准用于临床应用。本文的目的是提供 ACS 和 PCI 中新型抗血小板药物的最新概述，包括最新批准的药物以及临床开发中的新兴化合物的最新进展。
